Categories: Breast Cancer Treatment Tags: Advisory, Avastin, Committee, From, Meeting, Provides, Roche, Update
At Democrats’ meeting; Public is invited to Wyman’s talk
At Democrats’ meeting; Public is invited to Wyman’s talk
Lt. Gov. Nancy Wyman will address the Democratic Town Committee on Thursday, June 16, at 7:30 p.m. in the town hall meeting room. The public is invited. Connecticut’s second in command will present an overview of the recent legislative session. A question and answer session will follow. Before being sworn in alongside Gov. Dannel Malloy in January 2011, Nancy Wyman served as state comptroller …
Read more on Redding Pilot
Categories: Breast Cancer Information Tags: Democrats’, invited, Meeting, Public, talk, Wyman’s
BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting
BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the “Electrochemotherapy 1st International Users’ Meeting”(Bologna, Italy, November 19-20, 2010).
Read more on News-Medical-Net
Categories: Breast Cancer Pain Tags: AMEP, BioAlliance, Clinical, Electrochemotherapy, Meeting, Melanoma, Phase, preclinical, presents, Results
Enzon Presents Data at 2010 EORTC-NCI-AACR Meeting
Enzon Presents Data at 2010 EORTC-NCI-AACR Meeting
Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA antagonists. These antagonists are based on the locked nucleic acid technology platform targets licensed from Santaris Pharma A/S.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Tumor Tags: 2010, Data, Enzon, EORTCNCIAACR, Meeting, presents
Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting
Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting
Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).
Read more on News-Medical-Net